12m
Sanofi (ENXTPA:SAN) Is Up 5.7% After Dupixent’s Positive Phase 3 Results in AFRS—What's Changed
Sanofi announced positive results from the pivotal Phase 3 LIBERTY-AFRS-AIMS trial showing Dupixent significantly improved outcomes for adults and children aged 6 years and older with allergic fungal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback